Argus raised the firm’s price target on Danaher (DHR) to $265 from $255 and keeps a Buy rating on the shares. Danaher is well positioned for growth, the analyst tells investors in a research note. Through M&A and internal investments, the company has strengthened its ability to serve customers in the biotech, life sciences, and diagnostics industries, and its bioprocessing business, which provides equipment and consumables such a monoclonal antibodies to biotech manufacturers, is seeing strong demand as customers increase production of biologic medicines, the firm added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher: Buy Rating Reiterated on Broad-Based Outperformance and Premium-Justified Growth Outlook
- Danaher sees FY25 adjusted EPS ‘toward the high-end’ of $7.70-$7.80 range
- Danaher sees Q4 revenue growth in mid-single digit percent range y/y
- Danaher price target raised to $270 from $260 at TD Cowen
- Danaher price target raised to $250 from $245 at Evercore ISI